Effective Elimination of Lymphoma Cells in Stromal Microenvironment by Double Impact on ROS and ATP Metabolism Using Auranofin

Mengqi Yang,Panpan Liu,Huanting Chen,Jing Yang,Shijun Wen,Yumin Hu,Wenhua Lu,Ping Chen,Guoxin Hou,Weiye Jiang,Wenqi Jiang,Jinyun Liu,Peng Huang
DOI: https://doi.org/10.21203/rs.3.rs-55280/v1
2020-01-01
Abstract:Background Protection of cancer cells by the stromal microenvironment is an important drug-resistant mechanism in vivo, and poses a major challenge in cancer treatment. Based on our recent findings that auranofin (AF), an anti-rheumatic drug known to inhibit thioredoxin reductases (TrxR), was effective against several cancer models in vivo, this study tested the ability of AF to eliminate cancer cells in the tumor stromal microenvironment and investigated the underlying mechanisms. Methods Cytotoxic effect of AF on 33 cancer cell lines in vitro was determined by MTS assay to identify AF- sensitive cancer cells. Further cytotoxic effect of AF on the identified cancer cells was determined by flow cytometry analysis in stromal co-culture system. Mitochondrial bioenergetics assays using the Seahorse XF24 analyzer, mass spectrometry analyses, and enzyme activity assays were used in the mechanistic study. For in vivo study, lymphoma xenograft models were utilized to evaluate the in vivo therapeutic activity of AF in mice. Results We unexpectedly found that AF exhibited higher therapeutic activity against lymphoma cells in stromal microenvironment compared to lymphoma cell treated with AF without stromal cells. Mechanistic study showed that AF impacted energy metabolism by inhibiting the glycolytic enzyme GAPDH and suppressing mitochondrial electron transport complex II, leading to ATP depletion. Surprisingly, inhibition of TrxR seemed not critical for its anticancer activity, as genetic silencing of TrxR1 and TrxR2 did not significantly affect cell viability. Co-culture of lymphoma cells with stromal cells enhanced the expression of TrxR1, which became an ROS-generating molecule when interacting with AF. The AF-induced ATP depletion plus ROS generation together effectively killed the cancer cells in stromal microenvironment, and significantly suppressed tumor growth in mice bearing mantle cell lymphoma xenografts. Conclusions Our study reveals a novel mechanism by which AF eliminates cancer cells in tumor microenvironment by impacting cancer metabolism and promoting ROS generation, and suggests a possibility to repurpose this anti-rheumatic drug for treatment of lymphoma and overcome drug resistance in stromal microenvironment.
What problem does this paper attempt to address?